Compass Therapeutics Stock Return On Equity

CMPX Stock

USD 1.50 0.01 0.67%

Compass Therapeutics fundamentals help investors to digest information that contributes to Compass Therapeutics' financial success or failures. It also enables traders to predict the movement of Compass Stock. The fundamental analysis module provides a way to measure Compass Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Compass Therapeutics stock.

		Last Reported	Projected for Next Year
	Return On Equity	(0.29)	(0.30)

Return On Equity is likely to drop to -0.3 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Compass Therapeutics Company Return On Equity Analysis

Compass Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Compass Therapeutics Return On Equity

-0.32

Most of Compass Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Compass Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Compass Return On Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Compass Therapeutics is extremely important. It helps to project a fair market value of Compass Stock properly, considering its historical fundamentals such as Return On Equity. Since Compass Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Compass Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Compass Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Long Term Debt Total	Capital Surpluse	Net Receivables
Total Assets		0.9	0.87	0.58	-0.27	-0.85	0.67	-0.75	-0.76	0.9	0.71	1.0	-0.79	1.0	-0.83	-0.79	-0.43	-0.37	0.93	-0.37
Total Stockholder Equity	0.9		0.99	0.75	-0.21	-0.96	0.53	-0.95	-0.96	1.0	0.87	0.91	-0.96	0.9	-0.64	-0.96	-0.67	-0.57	0.91	-0.57
Net Tangible Assets	0.87	0.99		0.73	-0.14	-0.98	0.57	-0.94	-0.95	0.99	0.86	0.88	-0.94	0.88	-0.65	-0.94	-0.71	-0.67	0.93	-0.67
Current Deferred Revenue	0.58	0.75	0.73		-0.05	-0.79	0.22	-0.87	-0.83	0.75	0.96	0.59	-0.72	0.59	-0.18	-0.72	-0.7	-0.3	0.71	-0.3
Net Debt	-0.27	-0.21	-0.14	-0.05		0.05	0.34	0.16	0.19	-0.21	-0.12	-0.26	0.25	-0.27	0.3	0.25	-0.5	-0.27	-0.09	-0.27
Retained Earnings	-0.85	-0.96	-0.98	-0.79	0.05		-0.58	0.92	0.92	-0.96	-0.88	-0.86	0.88	-0.86	0.65	0.88	0.73	0.7	-0.95	0.7
Accounts Payable	0.67	0.53	0.57	0.22	0.34	-0.58		-0.36	-0.39	0.53	0.38	0.68	-0.44	0.69	-0.6	-0.44	-0.5	-0.42	0.73	-0.42
Long Term Debt	-0.75	-0.95	-0.94	-0.87	0.16	0.92	-0.36		0.99	-0.95	-0.95	-0.76	0.96	-0.75	0.39	0.96	0.76	0.53	-0.82	0.53
Total Liab	-0.76	-0.96	-0.95	-0.83	0.19	0.92	-0.39	0.99		-0.96	-0.93	-0.77	0.98	-0.77	0.42	0.98	0.75	0.54	-0.82	0.54
Net Invested Capital	0.9	1.0	0.99	0.75	-0.21	-0.96	0.53	-0.95	-0.96		0.87	0.91	-0.96	0.9	-0.63	-0.96	-0.68	-0.57	0.91	-0.57
Short Long Term Debt	0.71	0.87	0.86	0.96	-0.12	-0.88	0.38	-0.95	-0.93	0.87		0.72	-0.87	0.72	-0.31	-0.87	-0.74	-0.39	0.82	-0.39
Total Current Assets	1.0	0.91	0.88	0.59	-0.26	-0.86	0.68	-0.76	-0.77	0.91	0.72		-0.8	1.0	-0.82	-0.8	-0.46	-0.38	0.94	-0.38
Capital Stock	-0.79	-0.96	-0.94	-0.72	0.25	0.88	-0.44	0.96	0.98	-0.96	-0.87	-0.8		-0.8	0.46	1.0	0.69	0.51	-0.8	0.51
Net Working Capital	1.0	0.9	0.88	0.59	-0.27	-0.86	0.69	-0.75	-0.77	0.9	0.72	1.0	-0.8		-0.83	-0.8	-0.45	-0.38	0.94	-0.38
Short Term Debt	-0.83	-0.64	-0.65	-0.18	0.3	0.65	-0.6	0.39	0.42	-0.63	-0.31	-0.82	0.46	-0.83		0.46	0.07	0.48	-0.77	0.48
Common Stock	-0.79	-0.96	-0.94	-0.72	0.25	0.88	-0.44	0.96	0.98	-0.96	-0.87	-0.8	1.0	-0.8	0.46		0.69	0.51	-0.8	0.51
Property Plant Equipment	-0.43	-0.67	-0.71	-0.7	-0.5	0.73	-0.5	0.76	0.75	-0.68	-0.74	-0.46	0.69	-0.45	0.07	0.69		0.59	-0.6	0.59
Long Term Debt Total	-0.37	-0.57	-0.67	-0.3	-0.27	0.7	-0.42	0.53	0.54	-0.57	-0.39	-0.38	0.51	-0.38	0.48	0.51	0.59		-0.56	1.0
Capital Surpluse	0.93	0.91	0.93	0.71	-0.09	-0.95	0.73	-0.82	-0.82	0.91	0.82	0.94	-0.8	0.94	-0.77	-0.8	-0.6	-0.56		-0.56
Net Receivables	-0.37	-0.57	-0.67	-0.3	-0.27	0.7	-0.42	0.53	0.54	-0.57	-0.39	-0.38	0.51	-0.38	0.48	0.51	0.59	1.0	-0.56

Click cells to compare fundamentals

For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.

Competition

Predict Compass Therapeutics

Return On Equity Over Time

Compass Total Stockholder Equity

Total Stockholder Equity

155.96 Million

At this time, Compass Therapeutics' Total Stockholder Equity is fairly stable compared to the past year.

Based on the latest financial disclosure, Compass Therapeutics has a Return On Equity of -0.32. This is 98.66% lower than that of the Biotechnology sector and 99.12% lower than that of the Health Care industry. The return on equity for all United States stocks is 3.23% higher than that of the company.

Compass Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Compass Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Compass Therapeutics could also be used in its relative valuation, which is a method of valuing Compass Therapeutics by comparing valuation metrics of similar companies.

Compass Therapeutics is currently under evaluation in return on equity category among its peers.

Compass Fundamentals

	Return On Equity	-0.32
	Return On Asset	-0.22
	Operating Margin	(65.23) %
	Current Valuation	76.48 M
	Shares Outstanding	137.59 M
	Shares Owned By Insiders	12.04 %
	Shares Owned By Institutions	69.19 %
	Number Of Shares Shorted	1.79 M
	Price To Book	1.48 X
	Price To Sales	241.19 X
	EBITDA	(48.47 M)
	Net Income	(42.49 M)
	Cash And Equivalents	132.02 M
	Cash Per Share	1.31 X
	Total Debt	1.73 M
	Debt To Equity	0.03 %
	Current Ratio	12.36 X
	Book Value Per Share	1.01 X
	Cash Flow From Operations	(40.62 M)
	Short Ratio	3.71 X
	Earnings Per Share	(0.35) X
	Target Price	8.0
	Number Of Employees	32
	Beta	0.75
	Market Capitalization	205.01 M
	Total Asset	156.88 M
	Retained Earnings	(315.31 M)
	Working Capital	146.08 M
	Net Asset	156.88 M

About Compass Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Compass Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Compass Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Compass Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Compass Stock Analysis

When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC